Secreted proteins

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Incyte Corporation patent solves the following problem:

Protein transport and secretion is necessary for cellular function. Transport protein mediated a signal peptide located at amino terminal protein dad or hidden. The signal peptide consists of ten to twenty hydrophobic amino acids that target the nascent protein from ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Protein target the ER to continue by way secretory or stay in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory way be secreted into the extracellular space or left in the plasma membrane. Protein retained in the plasma membrane includes one or more transmembrane domains, each consisting of 20 hydrophobic amino acid residues. Secreted protein normally synthesized as inactive precursors because of the post-translation processing events during transit through the secretory way. Such events include glycosylation, proteolysis, and removal of the signal peptide with a signal peptidase. The other events that occur during the transport proteins include chaperone-dependent expression and folding of nascent proteins and protein interaction with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptide described below and include protein with an important role in cell-to-cell signaling. Such proteins include transmembrane receptor and cell surface markers, extracellular matrix molecules, cytokines, hormones, growth and diversity factor, enzyme, neuropeptides, vasomediators, cell surface markers, and antigen recognition molecules. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of the Cell, garland Publishing, New York, NY, pp. 557-560, 582-592.)

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7608704 B2 deals with Secreted proteins.
human invention provides secreted protein (SECP) and polynucleotides which identify and encode SECP. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with aberrant expression of SECP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Treatment of infection in animals

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mars, Inc. patent solves the following problem:

This application is the US National Stage of International Application No. PCT / GB01 / 01036, filed on March 9, 2001. This application further claims foreign priority PCT / Mb00 / 00890 filed on March 10, 2000, United Kingdom Using 0012401.6 filed May 22, 2000, and United Kingdom Using 0022210.9 filed on Aug. 11, 2000.

Our analysis of this patent is as follows:

Mars, Inc.’s patent US 7608291 B2 deals with Treatment of infection in animals.
The present invention relates to the use of a non-digestible carbohydrate in the form of a composition for treating or preventing pathogenic bacteria in the large intestine of a pet. It also provides a method for the prevention or treatment of a pathogenic bacteria in the large intestine of a pet, the method comprising administering said pet animal a composition comprising a non- digestible carbohydrate.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for producing hydroxylammonium salts

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Domo Caproleuna Gmbh patent solves the following problem:

The invention relates to a method of making hydroxylammonium salts in catalytic reduction of nitrogen monoxide with hydrogen in a diluted aqueous solution of mineral acid in the presence of platinum catalysts suspended in a support in many subsequent reaction round .

Our analysis of this patent is as follows:

Domo Caproleuna Gmbh’s patent US 7608236 B2 deals with Method for producing hydroxylammonium salts.
One way to make hydroxylammonium salts in catalytic reaction of nitrogen monoxide with hydrogen in a diluted aqueous solution of mineral acid in the presence of platinum catalysts suspended in a support in many subsequent reaction stages. This reaction occurs in a stirred reactor in which a gas inlet and distribution system is given at the bottom of the stirred reactor, a disk misleading placed immediately upon the birth center or face support and more angled, concave and tilted misleading blades that rotate their angled or concave sides in the direction of movement, and a two-edged misleading given the misleading shaft in the upper part of the stirred reactor, the individual leaves offset like lamellas that they always wet the reactor cap when rotating.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Protein hydrolysates enriched in peptides having a carboxy terminal proline residue

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Dsm Ip Assets B.V. patent solves the following problem:

Enzyme hydrolysates of cow's milk or pieces of cow's milk only limited application in the food industry. Nevertheless, these hydrolysates occupy interesting wall space in the market, as evidenced by the large number of literature describing and claiming optimized processes for obtaining such hydrolysates. Milk or milk fractions were subjected to enzymes with proteolytic activity to produce the hydrolysates primarily to minimize the allergenicity of the product, abdominal facilitate uptake by offering an easily absorbed thinking, and to strengthen the protein acid products against precipitation during prolonged periods of storage.

Our analysis of this patent is as follows:

Dsm Ip Assets B.V.’s patent US 7608697 B2 deals with Protein hydrolysates enriched in peptides having a carboxy terminal proline residue.
One way to enzymatically producing a protein hydrolyzate from a protein substrate is described, wherein a proline-specific endoprotease or a composition containing a proline-specific endoprotease and optionally one or subtilisin a metallo endoprotease, and other enzymes like the carboxypeptidases, used to make a protein hydrolyzate peptide fractions enriched with a carboxy terminal proline residue. The protein hydrolysates can be used as or to reduce the bitterness eat nutritionally supplemented with protein hydrolysates, as well as creating hydrolyzate containing foods with low antigenicity.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.